Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
doesn't matter when the news comes out, or if there were trading irregularities, the halt is for news pending, this is fact.
https://ca.finance.yahoo.com/news/iiroc-trading-halt-agn-191500315.html
Our CEO wrote a letter to personally thank all of you for supporting us along our journey as we complete enrollment for our multinational Phase 2b/3 trial of Ifenprodil for #COVID-19.
— Algernon Pharmaceuticals (@AlgernonPharma) December 14, 2020
We invite you to read the letter on our website.$AGN.CN $AGW $AGNPFhttps://t.co/hLrLXvYqef
Learn about Ifenprodil’s potential to become a leading therapeutic treatment in our featured @BNNBloomberg article.#AGNMultinationalTrial$AGN.CN $AGW $AGNPF #Stockshttps://t.co/sUwf1zq5Pm
— Algernon Pharmaceuticals (@AlgernonPharma) December 14, 2020
whoa, that was fast. We were hovering ~1 person a day enrollment, and now we get this amazing news 1 week after 50% mark (25 patients ~7 days). Enrollment picking up!!!! Wonder what changed.
interesting, after a data readout, their market cap is 300MM. Hopefully that's not the ceiling for a COVID treatment. Companies gained billions on lesser vaccine data.
ALGERNON ANNOUNCES ENROLLMENT OF FIRST PATIENT IN 2B/3 HUMAN STUDY OF IFENPRODIL FOR TREATMENT OF COVID-19 || TRIAL WILL BEGIN AS A PHASE 2B STUDY OF AN AGGREGATE OF 150 PATIENTS
— First Squawk (@FirstSquawk) August 5, 2020
around 2 hours left in the trading day, will we get news of enrollment or dosing? need to under promise and over deliver.
volume has been very high and steady the past few days, vs the times we were gradually descending into the teens
Next stock price inflection points are full enrollment, first patient dosing, any run up (or decline) going to 2 weeks for the trial, any "data" rumors, and the data itself.
I am so excited about this line:
price reflects we will be flat after this news release, sure why not, probably even end up red since we have 30 minutes left in the day :)
AMG hits the nail on the head IMO
Clearly posted needing more money, and now drastically don't need money.
Pump?
Nothing will move until the first patient is enrolled and dosed.
If they really can do it before July 2020 (less than a week), I think we will move. That shows something is ACTUALLY happening.
Otherwise any other speculative stock right now has been shooting ATHs, and we drag lower on news.
Not that my opinion matters...
lot of cricket chirps since last news...
hundreds of companies tackling vaccines, therapeutics, etc.
AGN has no sense of urgency.
I said it once and I'll say it again, AGN is dragging their feet. They are too busy playing Kal games for penny flipping nonsense.
From the BBC article posted earlier:
volume pretty low today compared to the past week
yep, he definitely did not enjoy Biopub. I think that was due to how ignorant the biopub people were. As another board member here mentioned, they were looking at their phones, basically not interested in delivering a high quality forum. For an hour that's pretty draining. The only person paying remote attention was YVR Trader and moderating questions.
haha I wish this was true, I feel like he just stumbled on his words a little.
Either way, thank you for linking the latest Proactive video, I didn't know they published a new one!
I could also be wrong but I agree with that sentiment and "felt like" (notice I said felt like, and didn't cite any sources) I heard the same thing. I think CEO said because it's an IND, depending on 2b, the length of time/size phase 3 is needed before approval is much different than the typical route of a brand new drug.
The 2022 date to me just seems like a safety buffer because a date is "needed".
I believe FDA approval only sets us a baseline support on share price, and does not trigger a run up. Whereas before the price was skeptical on approval, yet pricing in approval.
But I'm no MM, just a molecule in the scheme of AGN's trading future.
I doubt it will take until 2022 to see significant price movement, we'll get data out of 2b fairly soon after they start. 2 week trial mixed in with making sure they aggregate data from correct scans, etc.
SK was always treated as a side project, so they aren't focusing much energy on it. They even said so. AGN is focusing entirely on the multinational trial.
CEO explained in last webcast why they do halts, "to let people digest news and make it fair".
Dramatic for a US company? definitely. Companies are pumping out stuff mid day all the time unless it's insanely big news.
Dramatic for a Canadian company? No idea, unless anyone trades there normally and knows the typical behavior.
I did not expect a big share movement today. All in all, getting FDA approval just means it is countdown until data. Whereas the beginning of the countdown was somewhat a little more murky beforehand.
You can either flip pennies, or you can just wait on the data, who cares what happens in between. The final SP will reflect the data, whether 0.05 or $5.00, anything in between is a waste of time unless you're flipping.
Does anyone know if they'll begin the multinational trials without Australia? or will they still wait.
Honestly they should just start now that they have the biggest target audience.
Have there been historic cases of buyouts right after PPs? Seems counter-intuitive.
they just had PP and CEO went over the costs of the trials they want to run, do you all really think they're going to do another PP? That would just be insane. He made it sound like they have enough in the bank already (~2 mil and then add the PP ~6 mil)
Are companies that scummy that they do 2 PP's in a row???
I feel like they know they're diluted enough and would want to just bank on results of trials before raising more money since they just raised, why wouldn't they have just raised more earlier?
https://novotech-cro.com/covid-19-notice
you can download for SK, but doesn't say much, looks more like an advertising pamphlet
this was expected news, the stock is moving on nothing but traders trading and flipping.
approval from AUS/USA is what lets us know we are on track for starting the 2 week multinational trial
That or SK data
til then don't bother looking unless you're a trader trading
what irks me is the lack of news coming from SK trials, it's almost been 2 weeks.
I can understand Canada not starting yet, since the multinational trial they have stated would require 3 countries (USA, Canada, Australia) ethics approval before starting the 100 patient trial.
However SK is not part of that list and we've heard nothing, not even a first patient enrollment.
This Friday marks 2 weeks since enrollment of SK trials
Tomorrow marks Friday, one week since enrollment in SK... I hope we get news, silence is not golden here
I'm also confused by this trial, I thought they only needed a 2 week trial in Canada, yet the dates listed for completion are:
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : February 2022
glad to see some updated news on Canada, I wonder why they wait so long to start enrollment, guessing they want time to figure out SK results first
my feelings exactly
for me the interesting part of this news (and for any warrants news really) is the terms needed to be able to exercise. for this case it is